Gastroenterology Laboratory and the Division of Gastroenterology, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel
Holon Institute of Technology, Department of Digital Medical Technologies, Holon, Israel
New Microbiol. 2022 Jul;45(3):193-198.
Gastrointestinal (GI) microbial populations are important in maintaining normal functioning of the GI by preventing disorders. Dysbiotic microbiota may increase the likelihood of small intestinal bacterial overgrowth (SIBO), a syndrome associated with significant morbidity. We aimed to inves- tigate the microbiota populations of patients with SIBO. Patients with symptoms of SIBO were consecutively enrolled; they underwent a SIBO hydrogen breath test and stool was collected for microbiome analysis by sequencing of the 16S rRNA. Of the 55 patients recruited, 42 (76.4%) were positive for SIBO. When visualizing the bacterial β-di- versity, a sub-cluster of patients was identified. Further examination of these patients' records re- vealed previous treatment for Helicobacter pylori (HP). Microbiome analysis of these patients demonstrated a significant decrease in β-diversity (p-value<0.001) compared to patients without previous HP therapy. Furthermore, β-diversity was significantly different in this subgroup, and sev- eral bacterial taxa were differentially expressed, including one from the genus Methanobrevibacter, which was reduced in patients that previously underwent HP treatment. Our findings suggest that while symptoms associated with SIBO may cause dysbiosis, there was no differentiation in fecal microbiome composition based on SIBO diagnosis. Furthermore, our results support previous observations regarding antibiotic-altered microbiota with effects extending two and three years post-treatment.
胃肠道(GI)微生物群在预防疾病方面对维持 GI 的正常功能非常重要。失调的微生物群可能会增加小肠细菌过度生长(SIBO)的可能性,这是一种与严重发病率相关的综合征。我们旨在调查 SIBO 患者的微生物群。连续招募有 SIBO 症状的患者;他们接受 SIBO 氢呼气试验,采集粪便进行微生物组分析,方法是对 16S rRNA 进行测序。在招募的 55 名患者中,42 名(76.4%)SIBO 阳性。当观察细菌β多样性时,确定了一个亚群的患者。进一步检查这些患者的记录显示,他们之前曾接受过幽门螺杆菌(HP)治疗。与未接受过 HP 治疗的患者相比,这些患者的微生物组分析显示β多样性显著降低(p 值<0.001)。此外,该亚组的β多样性存在显著差异,几个细菌分类群存在差异表达,包括一个来自甲烷短杆菌属的细菌,该细菌在之前接受过 HP 治疗的患者中减少。我们的研究结果表明,虽然与 SIBO 相关的症状可能导致肠道菌群失调,但根据 SIBO 诊断,粪便微生物组组成没有差异。此外,我们的结果支持了先前关于抗生素改变微生物群的观察结果,其影响可延伸至治疗后两年和三年。